Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis

Mandi M. Murph1*, Wenbin Liu2, Shuangxing Yu1, Yiling Lu1, Hassan Hall1, Bryan T. Hennessy1, John Lahad1, Marci Schaner3, Åslaug Helland4,5, Gunnar Kristensen5,6, Anne-Lise Børresen-Dale4, Gordon B. Mills1

1 Department of Systems Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, 2 Department of Computational Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, 3 Department of Bioinformatics and Computational Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, 4 Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway, 5 Department of Gynecologic Oncology, The Norwegian Radium Hospital, Oslo, Norway, 6 Institute for Medical Informatics, The Norwegian Radium Hospital, Oslo, Norway

Abstract

Background: Lysophosphatidic acid (LPA) governs a number of physiologic and pathophysiologic processes. Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the initiation and progression of ovarian cancer. However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer.

Methodology and Principal Findings: In this study, gene expression profiling was used to examine LPA-mediated transcription by exogenously adding LPA to human epithelial ovarian cancer cells for 24 h to mimic long-term stimulation in the tumor microenvironment. The resultant transcriptional profile comprised a 39-gene signature that closely correlated to serous epithelial ovarian carcinoma. Hierarchical clustering of ovarian cancer patient specimens demonstrated that the signature is associated with worsened prognosis. Patients with LPA-signature-positive ovarian tumors have reduced disease-specific and progression-free survival times. They have a higher frequency of stage IIIc serous carcinoma and a greater proportion is deceased. Among the 39-gene signature, a group of seven genes associated with cell adhesion recapitulated the results. Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only independent biomarker of serous epithelial ovarian carcinoma. Knockdown of claudin-1 expression in ovarian cancer cells reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration.

Conclusions: The data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated expression signature in ovarian cancer that predicts a worse prognosis.

Introduction

The relationship between lysophosphatidic acid (LPA) and the tumor microenvironment remains poorly understood. Although LPA is secreted by ovarian cancer cells [1], found at elevated concentrations in ascites fluid [2–5], and LPA receptors are aberrantly expressed in ovarian cancer [6,7] it is not known whether LPA in the tumor microenvironment activates transcriptional events contributing to the etiology and/or progression of the ovarian cancers. The hypothesis that ascites-borne LPA functions in a pathophysiologic context is based on several observations. First, exogenous LPA causes cell proliferation, survival, invasion, migration and production of angiogenic factors likely to contribute to tumorigenesis [8]. Second, LPA receptor expression is altered in ovarian carcinomas [7,9]. Third, gene expression of LPPs, the naturally occurring enzymes that hydrolyze LPA, is decreased in a significant fraction of ovarian carcinomas [9]. Fourth, enforced expression of LPPs reduces ovarian cancer cell tumorigenesis [10]. Fifth, inhibitors of autotaxin (ATX), the enzyme that generates LPA, reduce both invasion and metastasis in vivo [11].

It is important to determine whether there is a relationship between LPA and patient outcomes since epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality for women in the U.S. [12]. Serous epithelial carcinoma accounts for about 70%...
Methods

Reagents and materials

LPA (18:1, 1-oleoyl-2-hydroxy-sn-glycero-3-phosphate) was purchased from Avanti Polar Lipids Inc (Alabaster, AL). OVCAR-3 ovarian epithelial adenocarcinoma and SKOV-3 ovarian serous adenocarcinoma cells were acquired from ATCC (Manassas, VA) and maintained in RPMI (CCSG Media Preparation Facility, The University of Texas M. D. Anderson Cancer Center, Houston, TX) supplemented with 10% FBS (Sigma, St Louis, MO). HT-29 human colon cancer cells were maintained in DMEM (CCSG Media Preparation Facility) supplemented with 10% FBS (Sigma). The claudin-1 antibody was purchased from Zymed (San Francisco, CA) and the GAPDH antibody was purchased from Applied Biosciences/Ambion (Austin, TX).

LPA-induced gene expression

OVCAR-3 cells were serum-starved prior to stimulation with 20 μM 18:1 LPA, 20 nM EGF or 2 μM TGFβ for 24 h to mimic long-term LPA influence in the ovarian tumor microenvironment. Pathological LPA concentrations range from 1 to 80 μM and LPA is rapidly degraded in vitro justifying the use of 20 μM LPA in the cultures. RNA was extracted using a Qiagen kit (Qiagen, Valencia, CA) and TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Gene expression microarray profiling was performed using triplicate samples on Affymetrix GeneChip U133A. GeneChips on an HTA system at the Life Sciences Division of the Ernest Orlando Lawrence Berkeley National Laboratory (Berkeley, CA). Data was uploaded to the GeneTraffic Bioinformatics server with GeneTraffic microarray database and analysis software (Stratagene/Agilent Technologies, La Jolla, CA) for raw image analysis, filtering and processing.

Data analysis for transcriptional signatures

Linear scale data from the GeneTraffic algorithm was transformed to log2. Significance Analysis of Microarrays (SAM) (20 R., and Chu, G. 2001), implemented as the R package samr (version 1.20) (http://www-stat.stanford.edu/~tibs/SAM/Rdist/index.html), was used for statistical analysis. The mean expression levels between the LPA-treated and the control groups for significant changes had parameters set such that resp.type = ‘Two class unpaired’, nperm = 100, testStatistic = ‘standard’, and delta = 0.5. The final cutoff q-value [21] was 5%. This resulted in 45 up-regulated transcripts, with repeats, giving 39 uniquely-expressed transcripts. Among these genes, 90% had a fold change ≥1.4.

Categorization of the LPA signature

Gene lists generated from microarray analysis were probed for biological themes using Expression Analysis Systematic Explorer (EASE) analysis tool [22]. This application converts gene lists into biologically relevant categories to aid the interpretation of microarray data. List results were converted into pie graphs using Microsoft Excel to aid visual interpretation.

Cluster analyses

Hierarchical clustering analyses used Cluster developed by the Eisen lab [23]. Genes were median centered prior to clustering. Cluster processed the data by selecting both genes and arrays and creating average linkage. The display of hierarchical clustering graphs utilized TreeView [23]. For hierarchical clusters, publicly-available ovarian cancer gene expression datasets (GSE6822 [24], GSE60908 [25], GSE10971 and GSE12418 [26]) were downloaded from the NCBI Entrez GEO website (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gds).

Real-time quantitative PCR

Transcripts in the 39-gene expression profile not previously implicated in LPA signaling were verified with real-time QPCR.
mRNA was extracted with GenElute Direct mRNA kit (Sigma Aldrich, St. Louis, MO). Using 300 ng of mRNA as a template, a reverse transcription reaction was performed using Superscript III kit (Invitrogen, Carlsbad, CA) to generate cDNA following the manufacturer’s protocol. Quantitative PCR was performed using SYBR Green PCR Master kit (Applied Biosystems, Foster City, CA). Reactions were normalized using the housekeeping gene, β2-microglobulin, and calculations were performed according to previous methods [27]. Primers used were based on algorithm-generated sequences from Primer Bank (http://pga.mgh.harvard.edu/primerbank/) [28]. The results presented used: ATF3 (5'-TCGCGCTGGAATCAGTCAC-3’ and 5'-GTGGGGCCGATGAAGGTTGA-3’); CLDN1 (5'-GGGCGATATTCTCCTTGCGAGG-3’ and 5'-TTCTGACCTGGCCATTGACTGGG-3’); ETV5 (5'-GCTGTGCTTGTAGCCATAGTA-3’ and 5'-GGAGTTCTGATGGTTGGGT-3’); EPAS1 (5'-GGAGGGTGTTCTATGAGCCGG-3’ and 5'-GGTTGTGTGTTGCTGCAGGAAG-3’); LDLR (5'-CTGTGCTGGGTAAGCTG-3’ and 5'-CAATGCTCTCAACCAAGCTCTG-3’); β2-microglobulin (5'-GGTGCCCTTACCTGCTGCTG-3’ and 5’-ACCTGAATGCTGGATACGCCCTC-3'); MUC1 (5’-AAGCAGCTCTGATGATAAACC-3’ and 5’-GGTACTCGCTCATAGGATGGT-3'); 2-microglobulin (5’-ACCTGAATGCTGGATACGCCCTC-3'); MUC1 (5’-AAGCAGCTCTGATGATAAACC-3’ and 5’-GGTACTCGCTCATAGGATGGT-3'); and SKIL (5’-AATCATCCAAAGCACATGACCC-3’ and 5’-AGTTTACACTACTGTGAGCC-3’).

Claudin-1 fluorescent visualization
Fluorescence imaging was done as previously described [17]. In order to assess the localization of claudin-1 after IPA addition, quiescent HT-29 and OVCAR-3 cells were stimulated with LPA (10 μM) for the times indicated and visualized using anti-claudin-1 primary antibody (1:200; Zymed) followed by Oregon Green-conjugated goat anti-mouse immunoglobulin G (1:500; Invitrogen/Molecular Probes) secondary antibody.

Boyden chamber migration assay
SKOV-3 cells (2×105) were transfected with reagent only, no siRNA (Mock), RISC-free control siRNA or claudin-1 siRNA. Forty-eight hours later, cells were seeded into the upper well of a membrane Boyden chamber and migration assay done as described [17]. Results were repeated and confirmed by crystal violet extraction using 10% acetic acid and measuring the OD at 590 nm.

Two-dimensional cell motility
SKOV-3 cells transfected with siRNA were grown to confluence. Two-dimensional cell motility assay was done as previously described [17]. Cells between monolayers were counted and data averaged over all experiments. Displayed photomicrograph images (4x) are representative of repeated experiments.

Western blot assessment of siRNA transfection
Protein from SKOV-3 cells transfected with siRNA was harvested and processed for Western blotting as previously described [17]. Immunoblots were probed with claudin-1 (Zymed) and GAPDH (Applied Biosciences/Ambion) antibodies and visualized with chemiluminescence. Band intensities were normalized to Mock control and represent the ratio of peak values.

Cell proliferation and viability
SKOV-3 cells transfected with siRNA using in motility studies were examined for viability by detecting cells from 12-well dishes and plating 3, 10 or 15, 20×103 cells in 96-well plates in quadruplicates. Cells were grown for 24 h in 1% medium before adding CellTiter™ Blue reagent (Promega, Madison, WI) to wells to measure viability as previously described [17].

Cell adhesion
OVCAR-3 cells were transfected with siRNA for 48 h prior to examination for cell adhesion. Cells were seeded at 5×103 cells in 96-well plates in quadruplicates for 2 h before multiple washings with PBS. Calcein-AM solution was then added to each well of the 96-well plate and fluorescence was measured.

Patient outcome, sensitivity, and specificity analyses
Patient data for disease-specific (DSS) and progression-free survival (PFS) were obtained from clinical reports. For this study, ovarian cancer specimens (N = 79) were obtained at the debulking surgical procedure from patients treated at the Department of Gynecological Oncology at The Norwegian Radium Hospital (NRH) during the period May 1992 to February 2003. Tumor tissues were obtained at primary surgery and were snap frozen in liquid nitrogen. Expression arrays were run on all tumor specimens (N = 79) and clinical data were available for 79 tumors. The median age of the patients at diagnosis was 60 years (range, 38–81). The stage distribution of these ovarian cancers at diagnosis was as follows: stage IB (1), stage IIC (6), stage IIIB (1), stage IIEC (5) and stage IV (17). The majority of ovarian cancers were of high grade (grade 1 (5), grade 2 (18), grade 3 (56)) and serous in histology (serous (65), endometrioid (4), mucinous (3), undifferentiated (2), mixed (1), clear cell (1), unclassified (3)). Fifty-seven patients developed progressive disease at a median of 15 months (range, 3–126). In those patients without disease progression, follow-up ranged from 77–126 months. Progression-free survival (PFS) was measured from the date of surgery to the date of ovarian cancer progression. Disease-specific survival was measured from the date of surgery to the date of death from ovarian cancer.

Sensitivity and specificity
The data were plotted in a Kaplan-Meier survival curve format using GraphPad Prism software, which automatically generates p values for the survival curve (GraphPad Software, Inc., San Diego, CA). To ascertain data quality, we employed two supervised classification analyses: linear discrimination analysis (LDA) and K-nearest neighbor classification (KNN). Four of the 60 patients that had reported PFS time had more than 10 missing values, and they were excluded before imputing missing data according to the following protocols: http://www-stat.stanford.edu/hastie/Papers/missing.pdf [29]. Using the statistical parameters, with leave-one-out cross-validation, we achieved high sensitivity (0.88 and 0.94 for LDA and KNN, respectively) and low specificity (0.0 and 0.25 for LDA and KNN, respectively) for predicting relapse. We also took the 52 patients that have long (>6 mo.) and short (<= 6 mo.) relapse time for the same kinds of supervised classification. Using the same methods, we obtained very low sensitivity (0.29 and 0 for LDA and KNN respectively) and high specificity (0.84 and 0.91 for LDA and KNN, respectively) for predicting short relapse. The overall error rates for LDA and KNN are 0.17 and 0.1, respectively, for the first analysis and 0.23 and 0.21, respectively, for the second analysis.

Statistical analysis
Experimental data was analyzed for statistical differences using an analysis of variance (ANOVA) followed by Bonferroni’s Multiple Comparison test or Tukey’s test between groups or student’s t-test for comparison when the two compared categories have variances assumed equal. Tests applied where indicated and
The 39-gene, LPA-mediated transcriptional signature encompasses carcinogenesis-related transcripts

In order to define a molecular signature regulated by LPA reflective of the ovarian tumor microenvironment, we employed microarray expression profiling using ascites-derived OVCAR-3 ovarian adenocarcinoma cells. Our intention was to uncover LPA-induced transcriptional changes that result from long-term autocrine and paracrine LPA signaling in the tumor microenvironment. For this purpose we stimulated OVCAR-3 cells in culture with LPA (20 μM) for 24 h to mimic chronic exposure. We analyzed the microarray results using the statistical analysis of microarray (SAM) program, which yielded 45 positive hits. The results included several transcript repeats, totaling 39 different genes altogether to comprise a “39-gene” signature (Table 1). LPA has been demonstrated to regulate six of these genes, including CXCL1 [30], CTR61 [31], EGR1 [32], IL-8 [33], FN1 [34] and PLAU [35], while the remainder were known genes that had unknown associations with LPA. FN1, MUC1, SCD and THBS1, appear more than once providing a level of signature validation.

To determine the data quality, we created pairwise scatter plots and cross-compared the triplicate microarray data using control (Figure S1A), LPA treated (Figure S1B) and EGF treated (Figure S1C) samples. The scatter plots demonstrate a high degree of reproducibility with microarray replicates, falling close to a 45° reference line. The statistical corroboration enhances the likelihood that transcripts, which have no known connection to LPA are legitimate targets.

For further verification, we performed a time course followed with quantitative RT-PCR on the majority of transcripts with unknown associations to LPA, excluding CXCL1, CTR61, EGR1, IL-8, FN1 and PLAU. Thus, we analyzed 88% (N = 29) in OVCAR-3 and 91% in SKOV-3 (N = 30). SKOV-3 cells were selected to determine the generalizability of the results obtained with OVCAR-3 cells. The data shown confirms LPA-mediated modulation of expression among the transcription factors, ATF5, EPIAS1, ETV5 and SKIL (transcriptional co-repressor), appearing in the gene expression microarray data (Figure S1D). During this verification process of the 39-gene signature, we uncovered two genes, LOX and TNFAIP3, increased in the microarray results but decreased in quantitative RT-PCR (asterisk in Table 1 and data not shown). The reason for the differential response in the two assays remains unknown.

Using EASE, we classified the 39 genes comprising the LPA signature into two groups: cellular localization and molecular function. The principal location of one third of 39 genes was the plasma membrane (Figure S1E). The next most common location was the cytoplasm (26%). Interestingly, over half of the genes in the signature produce secreted proteins (20%) or proteins that are found in organelles of the cell that would allow extracellular signaling, like the extracellular matrix (12%) and plasma membrane (30%). We examined the molecular function of the 39-gene LPA signature, cell-cell communication was the leading represented category (21%) followed by signal transduction (14%) (Figure S1F). A wide variety of molecular functions were also included such as cell growth (13%), adhesion (13%), proliferation (11%), general cell metabolism (9%), lipid metabolism (7%) and products associated with the regulation of either survival or apoptosis (5%). The 39-gene, LPA-mediated signature correlates with serous carcinoma and worse prognosis in ovarian cancer patients

Hierarchical clustering using the 39-gene signature and an ovarian cancer training dataset from M.D. Anderson Cancer Center with control/non-malignant and serous EOC revealed a highly similar pattern among patient specimens (data not shown). The training data suggested LPA influences the development of serous EOC and/or the 39-gene signature characterizes serous EOC. To test these hypotheses, we analyzed additional datasets including a test dataset (GSE6008; N = 103) [24] containing normal ovary specimens and ovarian tumors from endometrioid, mucinous, serous and clear cell types.

Hierarchical clustering analysis of GSE6008 demonstrated that the most positive cluster for the 39-gene signature contained only serous specimens (N = 19, 100%) (Figure 1, far right cluster). Within the overall hierarchical clustering results, the gene expression dataset was divided into two major groups (N = 55 and 44) with normal ovary (N = 4) in the middle, separating the two. The group on the right (N = 55) that contained the highly positive LPA-signature cluster and additional clusters varying in LPA-signature-likeliness, consisted primarily of serous (N = 29, 71%, P < 0.001) or endometrioid (N = 23, 62%, P = 0.016) tumors.

The group on the left (separated by normal samples) exhibited expression patterns which deviate from the LPA-signature and consisted of clear cell (100%, P = 0.002), mucinous (77%, P = 0.018), endometrioid (38%, P = 0.016) and a portion of serous (29%, P < 0.001) tumors. It is important to note that the majority of the serous tumors on the left side show a distinct expression pattern that deviates from clear cell and mucinous tumors that are negative for the LPA-signature.

To further verify that 39-gene signature characterizes serous EOC, we examined additional ovarian datasets. The dataset GSE6922 (N = 74) [25] contains a majority of serous specimens (N = 46, 62%) and includes benign, borderline and invasive tumors. It is extremely difficult to acquire reliable, high-quality ovarian cancer datasets that include patient outcomes, as few are publicly available. Thus, the dataset we acquired has some incomplete data (gray shaded areas) and missing genes but we nonetheless used it for analysis knowing this limitation. Hierarchical clustering separated a group (N = 19) that was strongly positive for the LPA-signature (Figure S2A, far right cluster). The majority of tumors within this cluster are invasive serous tumors (63%) with a greater proportion of invasive tumors (90%) than other clusters (78%). Among the other clusters, which do not represent a likeness to the LPA-signature, the invasive serous is underrepresented (36% of the remaining tumors), whereas benign serous (83%) and borderline serous (88%) tumors are highly represented. In addition, these other clusters comprise a variety of ovarian tumor types such as clear cell (15%), endometrioid (13%), undetermined origin (11%), mixed (2%) and mucinous (2%), while the LPA-signature is strongly dominated by serous tumors (74%) and has no endometrioid, mucinous or tumors of undetermined origin. Over half of all serous tumor cells are invasive (malignant) and the remaining are borderline (low malignant potential) or benign [14].

Another dataset GSE10971 (N = 37) contains samples from non-malignant fallopian tube epithelium and high-grade serous carcinoma. Hierarchical clustering divided the samples into two groups (data not shown). Among the LPA-positive cluster, all samples were high-grade serous (N = 12, 100%) and among the dissimilar cluster, nearly all samples were non-malignant (N = 24, 96%) (Figure S2B). Only one sample from the latter group was high-grade serous (N = 1, 4%). In summary, the data from our
Table 1. Gene expression microarray results showing genes comprising the statistically-significant 39-gene LPA transcriptome signature in OVCAR-3.

| Probe ID   | Symbol     | Description                                                                 | Fold change | q-value (%) |
|------------|------------|-----------------------------------------------------------------------------|-------------|-------------|
| 206632_s_at| APOBEC3B   | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B          | 1.8724      | 2.377       |
| 202672_s_at| ATF3       | activating transcription factor 3                                            | 2.3955      | 0           |
| 218182_at  | CLDN1      | claudin 1                                                                    | 1.7331      | 4.5221      |
| 204470_at  | CXCL1      | chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) | 1.7242      | 4.5221      |
| 210764_s_at| CYR61      | cysteine-rich, angiogenic inducer, 61                                        | 1.722       | 2.377       |
| 204135_at  | DOC1       | downregulated in ovarian cancer 1                                            | 2.2444      | 0           |
| 203498_at  | DSCR1L1    | down syndrome critical region gene 1-like 1                                 | 1.9364      | 0           |
| 201694_s_at| EGR1       | early growth response 1                                                      | 1.446       | 0           |
| 201313_at  | ENO2       | enolase 2 (gamma, neuronal)                                                  | 1.5517      | 0           |
| 200878_at  | EPAS1      | endothelial PAS domain protein 1                                              | 1.3329      | 4.5221      |
| 203494_s_at| ETV5       | ets variant gene 5 (ets-related molecule)                                    | 1.3894      | 4.5221      |
| 205014_at  | FGFBP1     | fibroblast growth factor binding protein 1                                   | 2.5373      | 0           |
| 217199_x_at| FNI        | fibronectin 1                                                                | 2.3993      | 2.377       |
| 212464_s_at| FNI        | fibronectin 1                                                                | 2.2809      | 2.377       |
| 216442_x_at| FNI        | fibronectin 1                                                                | 2.2851      | 2.377       |
| 201631_s_at| IER3       | immediate early response 3                                                   | 1.857       | 0           |
| 202421_at  | IGSF3      | immunoglobulin superfamily, member 3                                         | 1.2985      | 4.5221      |
| 202859_x_at| IL8        | interleukin 8                                                                | 3.9342      | 0           |
| 218963_s_at| KRT23      | keratin 23 (histone deacetylase inducible)                                   | 1.9027      | 0           |
| 202068_s_at| LDLR       | low density lipoprotein receptor (familial hypercholesterolemia)             | 1.5159      | 0           |
| 220158_at  | LGALS14    | lectin, galactoside-binding, soluble, 14                                     | 1.6646      | 0           |
| 215446_s_at| * LOX      | lysyl oxidase                                                                | 1.4016      | 2.377       |
| 212233_at  | MAP1B      | microtubule-associated protein 1B                                             | 1.9061      | 0           |
| 207847_s_at| MUC1       | mucin 1, transmembrane                                                       | 1.7853      | 0           |
| 211695_x_at| MUC1       | mucin 1, transmembrane                                                       | 2.0686      | 4.5221      |
| 211017_s_at| NF2        | neurofibromin 2 (bilateral acoustic neuroma)                                 | 1.4298      | 0           |
| 219369_s_at| OTUB2      | OUT domain, ubiquitin aldehyde binding 2                                     | 1.511       | 4.5221      |
| 211668_s_at| PLAU       | plasminogen activator, urokinase                                             | 1.6944      | 2.377       |
| 204286_s_at| PMAIP1     | phorbol-12-myristate-13-acetate-inducible protein 1                          | 1.4263      | 0           |
| 210138_at  | RG520      | regulator of G-protein signaling 20                                          | 1.5114      | 2.377       |
| 200831_s_at| SCD        | stearyl-CoA desaturase (delta-9-desaturase)                                  | 1.4012      | 0           |
| 200832_s_at| SCD        | stearyl-CoA desaturase (delta-9-desaturase)                                  | 1.375       | 2.377       |
| 206884_s_at| SCEL       | sclelin                                                                      | 1.823       | 0           |
| 33323_r_at  | SFN        | stratifin                                                                    | 1.8976      | 2.377       |
| 206675_s_at| SKL        | SKI-like                                                                     | 1.3488      | 2.377       |
| 202856_s_at| SLC16A3    | solute carrier family 16 (monocarboxylic acid transporter)                   | 1.6286      | 2.377       |
| 201195_s_at| SLC7A5     | solute carrier family 7 (cationic amino acid transporter, y+ system) member 5 | 1.6561      | 0           |
| 201109_s_at| THBS1      | thrombospondin 1                                                             | 1.9995      | 0           |
| 201110_s_at| THBS1      | thrombospondin 1                                                             | 2.085       | 0           |
| 219058_x_at| TINAG1     | tubulointerstitial nephritis antigen-like 1                                 | 1.4088      | 2.377       |
| 217875_s_at| TMEPA1     | transmembrane, prostate androgen induced RNA                                 | 1.9765      | 0           |
| 201645_at  | TNC        | tenascin C (hexabrachion)                                                     | 1.5708      | 0           |
| 202643_s_at| * TNAF3P2  | tumor necrosis factor, alpha-induced protein 3                               | 1.8922      | 0           |
| 202644_s_at| * TNAF3P3  | tumor necrosis factor, alpha-induced protein 3                               | 1.6207      | 0           |
| 212242_at  | TUBA1      | tubulin, alpha 1 (testis specific)                                           | 1.9468      | 0           |

*Denotes decrease in transcript analyzed during verification using real-time QPCR.

doi:10.1371/journal.pone.0005583.t001
training set combined with the data presented using GSE6822, GSE10971 and GSE6008 datasets suggests that the LPA-signature characterizes serous EOC.

Since evidence suggests the 39-gene signature characterizes serous EOC from ovarian datasets (Figure 1, Figure S2A and S2B, and data not shown), we questioned whether it also classified prognosis in ovarian cancers. For this analysis, we acquired two ovarian cancer datasets containing patient outcomes. The first dataset (GSE12418; N = 54) [26] was used to examined the predictive value of the 39-gene signature and it contains serous samples from different stages. Hierarchical clustering separated the specimens into two groups (Figure 2A) based largely upon drivers \( \text{THBS1}, \text{EGR1}, \text{EPAS1}, \text{CIRG61}, \text{FN1} \) and \( \text{PLAU} \). The LPA-signature-positive cluster (N = 24) contained a greater portion of samples from stage IIIc patients (N = 20, 83%, \( P = 0.01 \)) than the dissimilar cluster that was evenly split among stage IIIa, IIIb and IIIc (Figure 2B). Although not statistically significant, samples in the LPA-positive cluster also contained more deceased patients (N = 18; 67%) than the dissimilar cluster (N = 16, 53%) (Figure 2C).

The second ovarian cancer dataset containing patient outcomes that we used for the prognosis analysis is a large EOC dataset (N = 79, see METHODS for more details) of specimens acquired from patients treated at the Norwegian Radium Hospital. Briefly, the ovarian cancer specimens were obtained at the debulking surgical procedure from primary tumors. Hierarchical clustering separated the patients into three groups (Figure 2D) based largely upon drivers \( \text{ATF3}, \text{CIRG61}, \text{EGR1}, \text{FN1} \) and \( \text{PLAU} \) and to some extent \( \text{MUC1} \). Clustering the three groups distinguishes the most positive cluster (LPA-positive, N = 33), a negative cluster (LPA-negative, N = 33) and a smaller cluster with differentially expressed genes (Other, N = 13) that has a distinct pattern from the other groups. The Other cluster falls between the LPA-positive and -negative clusters and could represent either a transitional state of development between the two or a distinct set of ovarian tumors driven LPA in the context of other factors.

The LPA-signature-positive cluster comprises significantly shorter median values for both disease-specific (29 months, \( *P = 0.017 \)) (Figure 2E) and progression-free (15 months, \( *P = 0.025 \)) survival (Figure 2F) compared to the LPA-negative cluster, which had median values of 58 and 25 months, respectively. Statistical analysis of our findings indicated that this classification had high sensitivity (0.88 and 0.94 for LDA and KNN, respectively) for predicting relapse and high specificity (0.84 and 0.91 for LDA and KNN, respectively) for predicting short relapse. Taken together, our analysis of the 39-gene signature in prognosis of ovarian cancer suggests the signature represents markedly reduced progression-free and disease-specific survival and overall a worsened prognosis.

Claudin-1 is a biomarker for serous ovarian cancer and transcriptionally regulated by LPA to facilitate ovarian cancer cell adhesion

As therapeutics against LPA begin to enter clinical trials [36], a biomarker capable of distinguishing among subtypes of EOC could provide an extremely valuable classifier to select those ovarian cancer patients who are most likely to benefit from LPA-targeted drugs. Within the 39-gene LPA signature, we sought to determine whether such a biomarker existed. Among hierarchical
clustering analyses, particular gene expression transcripts repeatedly drive clustering and patient categorization. More specifically, a combination of ATF3, CLDN1, CXCL1, CRY61, EGR1, FNI, IL-8, MUC1, PLAU, THBS1 and TNC determine the LPA-positive clusters (Figure 1, Figure S2, Figure 2A and 2D, and data not shown) when these genes are included on the microarray chip. Among these drivers, we sought to determine whether a singular transcript is responsible for LPA-positive signature characterization.

Using the most complete dataset we acquired, (GSE60088; N = 105) [24], we analyzed the drivers and determined whether classification of LPA-positive serous tumors could be achieved using only CLDN1, CRY61, FNI, IL-8, MUC1, PLAU, THBS1 and TNC (Figure S3A). The comprehensiveness of the dataset we selected was based on the large number of samples, numbers of gene transcripts on the microarray and diversity of tissue samples. Using the available cell adhesion proteins, we revisited the data on specimens acquired from patients at the Norwegian Radium Hospital and found that hierarchical clustering of these genes was able to recapitulate the prognosis trends we previously observed for disease-specific and progression-free patient survival (Figure S3B and S3C). Out of the seven drivers in this dataset, claudin-1 (CLDN1) was sufficient to differentiate serous from other EOC types (Figure S3D). In comparison, serous carcinoma samples expressed high levels of CLDN1 whereas mucinous and normal were low and clear cell levels were the lowest. The endometrioid samples included a few patients with high claudin-1 expression (N = 4, 11%) but the majority of samples were at the median level or below (N = 52, 89%). Further analyses showing individual normalized comparison of gene expression levels (Figure 3) demonstrates that CLDN1 distinguishes serous from normal, clear cell, endometrioid and mucinous and is expressed at elevated levels in serous (P<0.001) (Figure 3H).

Thus, we next sought to determine the association between LPA and claudin-1 in ovarian cancer cells. Gene expression profiling of CLDN1 in OVCAR-3 cells after 24 h of stimulation with LPA (20 μM), EGF (20 μM) or TGFβ (2 μM) demonstrated LPA-selectively increased CLDN1 expression (Figure 4A). To confirm these results, we measured mRNA changes using quantitative, real-time PCR and noted that LPA (10 μM) significantly increased CLDN1 (P<0.01) compared to EGF (10 μM) after 24 h of agonist treatment (Figure 4B). The LPA-mediated increase in CLDN1 is maximal between 4 to 8 h after LPA (10 μM) treatment, when the relative ratio is approximately 20 times above normalized control (Figure 4C) CLDN1 levels remain elevated at 24 h at approximately 1.5 to 3 times control levels (Figure 4C).

We next stimulated OVCAR-3 and HT-29 colon cancer cells with 10 μM LPA for various times and examined effects on claudin-1 localization. HT-29 cells were used as a model for comparison to OVCAR-3 because claudin-1 is a regulator of metastasis in colon cancer [37] and not all cell types express claudin-1. Within 30 min after LPA stimulation, claudin-1 redistributed from the nuclear region to cell junctions in HT-29 cells. In contrast at 30 min of incubation with OVCAR-3 cells, most of the claudin-1 staining was nuclear and only some occurred on the plasma membrane and cell junctions (Figure 4D). Similar claudin-1 staining was seen in OVCAR-3 at 240 min post LPA stimulation (data not shown). However, intense cell junction staining occurred at 1440 min after LPA addition (Figure 4D, bottom right). Taken together, the data suggests that LPA induces increase in mRNA levels for CLDN1, which is not replicated by EGF, and LPA localizes claudin-1 to cell junctions in OVCAR-3 and HT-29 cells.

The previous results lead us to question whether the increase and relocalization of claudin-1 altered cell adhesion in OVCAR-3 cells. We thus analyzed cell adhesion in the presence of LPA after manipulating claudin-1 expression. Indeed, 10 μM LPA significantly enhances OVCAR-3 cell adhesion under all transfection conditions (Mock, RISC-free and siCldn1) when compared to transfected cells without LPA present (Figure 4E, white vs. black bars). A reduction in claudin-1 expression significantly reduced the ability of LPA to enhance adhesion (Figure 4E). Taken together, the data suggests that LPA enhances the adhesion of OVCAR-3 cells in part through increased expression and membrane localization of claudin-1.

Claudin-1 localizes to tight junctions and plays a role in cell adhesion. However a major reported role of LPA in ovarian cancer cell signaling is induction of motility. To evaluate the role of claudin-1 in ovarian cancer cell migration, we performed a series of functional migration assays after manipulating claudin-1 expression in SKOV-3 cells using siRNA. Claudin-1 levels were decreased approximately 60% (Figure 5A). SKOV-3 cells were selected instead of OVCAR-3 cells because OVCAR-3 cells are not motile and SKOV-3 cells are highly motile and responsive to LPA [38]. SKOV-3 cells are a relevant model system since they also show a similar LPA-mediated increase in CLDN1 to OVCAR-3 cells at 24 hours (Figure 5B) and they independently verified the 39-gene signature (Table 1 and Figure S1).

Wounding confluent monolayers of SKOV-3 cells stimulated with LPA (10 μM) and transfected with Mock-, RISC-free- or claudin-1 siRNA showed an similar effects on healing in response to LPA after 24 h (data not shown). Similar results were achieved with proliferation assays (data not shown) where no significant changes were measured comparing SKOV-3 cells with reduced claudin-1 to controls. SKOV-3 cells with reduced claudin-1 were also examined without exogenous LPA to determine their ability to heal a wounded cell monolayer. We detected an inability to seal wounded monolayers within 24 h, a process requiring LPA. We also detected an abundance of detached cells floating throughout the medium in wells with reduced claudin-1 expression (Figure 5C). It is unclear what percentage of suspended cells observed in the gap between monolayers were attached (reseeded cells) or not

Figure 2. The LPA signature corresponds to worsened outcome in ovarian cancer patients. (A) The patient dataset, GSE12418, N = 54, was downloaded from the NCBI Entrez GEO DataSets website and analyzed for gene expression changes among all included transcripts in the 39-gene signature, hierarchical clustering using the available genes divided patient samples into two groups, LPA-positive (N = 24) and dissimilar (N = 30) clusters, based largely upon the drivers THBS1, EGR1, EPAS1, CYR61, FNI and PLAU. (B) Separating the clusters based on stage IIb or IIIC patients (N = 20, 83%, P = 0.001) among the LPA-positive cluster whereas the dissimilar cluster is evenly split between stage IIb and IIIC. (C) Patient samples in the LPA-positive cluster also contained a greater percentage of deceased patients (N = 18; 67%) than the dissimilar cluster (N = 16, 53%). Results from C were not statistically significant. (D) Specimens (N = 79) isolated from patients treated at the Norwegian Radium Hospital (see METHODS) were analyzed by gene expression profiling. Hierarchical clustering of available genes included in the 39-gene signature separated the patients into three groups (LPA-positive, N = 33; LPA-negative, N = 32; Other, N = 13) based largely upon drivers ATF3, CYR61, EGR1, FNI and PLAU. Kaplan-Meier analysis of the different clusters indicates that the LPA-signature positive cluster has shorter median values for both disease-specific (29 months, P = 0.017) and progression-free (15 months, P = 0.025) survival (F) compared to the LPA-negative cluster (median values of 58 and 25 months, respectively). doi:10.1371/journal.pone.0005583.g002

LPA Gene Expression Profile

PLoS ONE | www.plosone.org 8 May 2009 | Volume 4 | Issue 5 | e5583
**Figure 3. CLDN1 is a biomarker for serous epithelial ovarian carcinoma specimens.** Box-plot analyses of data from GSE6008, N = 103 show the drivers THBS1 (A, B), TNC (C), IL-8 (D), MUC1 (E, F), CYR61 (G), CLDN1 (H), KRT23 (I) and FN1 (J, K, L) normalized comparison of gene expression levels. Among all previously-identified drivers in hierarchical clustering, the data demonstrates that CLDN1 is the only one which distinguishes serous when compared with normal, clear cell, endometrioid and mucinous (***P<0.001). The box represents the range of values and the center vertical line inside the box represent the median with whiskers representing the extended range. Results were analyzed by ANOVA and Tukey’s Multiple comparison post test; **P<0.05, ***P<0.01 and ****P<0.001 of ovarian tumor type vs. normal samples.

doi:10.1371/journal.pone.0005583.g003
Figure 4. LPA mediates cell adhesion through claudin-1 in OVCAR-3 cells. (A) OVCAR-3 cells were stimulated with either LPA (20 μM), EGF (20 μM) or TGFβ (2 μM) for 24 h before processing for Affymetrix gene expression microarray. CLDN1 expression was normalized to untreated controls and compared to agonist-stimulated conditions. Results are the average of triplicate samples. Results were analyzed by ANOVA and Bonferroni’s post test; *p<0.05, LPA vs. Control. (B) OVCAR-3 cells were stimulated with either LPA (10 μM) or EGF (10 μM) for 24 h and processed for quantitative RT-PCR (see methods) to measure transcriptional activity comparing selected transcripts from the 39-gene signature, claudin-1 (Cldn1), SKI-like oncogene (Skil) and low density lipoprotein receptor (LDLR). Results were normalized to β2-microglobulin and reflect the average of triplicate samples repeated in four independent assays. Results were analyzed by ANOVA and Bonferroni’s post test; **p<0.01, LPA vs. EGF. (C) A timecourse of LPA (10 μM) stimulated OVCAR-3 cells was performed for the times indicated using quantitative RT-PCR. Results show a representative experiment.
that was repeated in OVCAR-3 and SKOV-3 cells. ***p<0.001 for 1,4,8 and 24 h time points compared with normalized control. (D) Quiescent HT-29 and OVCAR-3 cells were stimulated with LPA (10 μM) for the times indicated and visualized using anti-claudin1 primary antibody followed by Alexa goat anti-mouse fluorescent secondary. (E) OVCAR-3 cells were transfected with siRNA targeting claudin-1 for 48 h. Cells were then trypsinized and replated for 2 h in the presence or absence of LPA (10 μM) and analyzed for adhesion. Results were analyzed by ANOVA and Bonferroni’s post test; *p<0.05 (RISC with LPA vs. siCldn1 with LPA) and **p<0.01 (Mock with LPA vs. siCldn1 with LPA).

doi:10.1371/journal.pone.0005583.g004

Discussion

Herein we present several important findings: first, a 39-gene, LPA-mediated signature identifies serous EOC as being different from with other types of EOC; second, the 39-gene signature correlates with worsened prognosis; third, a group of 7 genes is sufficient to categorize the LPA signature; fourth, a single biomarker, claudin-1, is increased in serous EOC and claudin-1 mRNA levels are increased by LPA; fifth, LPA induced claudin-1 localization to the plasma membrane; sixth, claudin-1 is involved in LPA-mediated adhesion and migration. The 39-gene expression signature was defined using OVCAR-3, an ascites-derived serous EOC cell line. Given that elevated levels of LPA are present in the vast majority of ascites fluids, OVCAR-3 is likely to have been exposed to LPA in the tumor microenvironment, making it an ideal model. It is intriguing that LPA stimulation was necessary in order to define a gene expression profile reflective of serous ovarian cancers suggesting that in vivo serous ovarian cancers are exposed and responding to LPA. A number of components in the 39-gene signature have been identified in previous ovarian candidate gene studies [39–41] and other genes have known associations with LPA [30–35]. However, the signature contains transcripts previously unassociated with LPA, such as CLDN1, and additional experiments are underway to elucidate these connections.

Using gene expression analysis and mining through ovarian cancer patient datasets, we demonstrate that the 39-gene signature characterizes serous EOC and a worsened prognosis. Comparing disease specific survival and progression free survival of LPA-signature-positive versus dissimilar groups, the LPA-positive patients exhibit a significantly reduced time of survival. This is remarkable considering that the preeminent biomarker among the 39-gene signature, claudin-1, was unfortunately absent from this ovarian dataset.

Additionally, the worsened prognosis classified by the 39-gene signature is observed when the comparison is made between serous samples in different disease stages. Among serous specimens, the LPA-positive group had a greater percentage of stage IIIc serous carcinoma than stage IIa and IIb. This observation is indicative of prognosis because the 3-year survival for stage IIa and IIIc carcinomas is 41.4% and 23.4%, respectively.

The fact that claudin-1 was not included in every prognosis dataset we analyzed indicates that the prognostic ability of the 39-gene signature is not reliant upon any singular gene expression change, but rather likely represents the conglomerate result of systematic changes resulting from LPA-induced changes in RNA levels. We did, however, observe an ability to recapitulate the serous EOC clustering using an abbreviated 7-gene signature that included CLDN1, CYR61, FN1, IL-8, MUC1, TNC and THBS1. Using these seven drivers, similar (and even enhanced) results were achieved compared to using all 39-genes. It is possible that these seven along with a few others (i.e. ATF3, EGR1, CXCLI, etc.) represent the majority of the effects mediated by LPA in the tumor microenvironment and that the others represent non-specific, growth-factor induced transcriptional activity that could be related to homeostatic regulation. Among signature drivers and the seven drivers changes, many have known associations with LPA, including CXCLI [30], CYR61 [31], EGR1 [32], IL-8 [33], FN1 [34] and PLAU [35].

In this study CLDN1 is elevated in serous EOC and sufficient to cluster ovarian tumor types, which suggests it, by itself, is an ovarian cancer-type biomarker but not a prognostic biomarker. This is in agreement with a previous study that distinguished between endometrioid and serous carcinoma using immunohistochemistry and claudin 1–7 expression [42]. Another independent study found claudin-1, claudin-3 and claudin-7 up-regulation together in ovarian cancer effusions predicts poor progression-free and overall survival [43]. Unlike the aforementioned studies, ours deviates because we use gene expression profiling, claudin-1, but not claudin-3, -4 or -7 and we also include normal, mucinous and clear cell tumors to further suggest that claudin-1 could distinguish serous from the other histologic types. We were unable to assess a prognostic ability of claudin-1 alone, in part because claudin-1 was not available on the earlier microarray profiling used to collect some of the patient data for analyses.

This study reports the novel observations that LPA markedly increases claudin-1 transcription and enhances its localization to the plasma membrane, likely into tight junctions. Cells lose adhesion with the loss of tight junctional proteins, like claudins, thus allowing the acquisition of migratory capabilities [44]. With reduced claudin-1 expression, the data shows a decrease in OVCAR-3 adhesion, an inhibition in LPA-mediated Boyden chamber migration in SKOV-3 cells and may reflect an inability of cells to attach to the substratum required for Boyden chamber migration through pores. This is a significant effect because motility is a major effect of LPA on SKOV-3 cells.
matrix, adhere to other cells, perform intravasation, survive turbulent anoxic conditions in the circulation and complete extravasation to invade new tissues. The ovaries are located in the peritoneal cavity, creating a uniquely passive, and comparatively uncomplicated, metastasis scenario. Malignant ovarian tumor cells floating in ascites fluid or peritoneal washings are detected in stage Ic ovarian cancer and above [45], making cells shed from the primary ovarian tumor commonly observed in this disease. These shed cells are then passively transported by peritoneal fluid and can seed on surrounding tissues if they acquire the ability to implant on peritoneal surfaces [15,45]. What molecular proteins would be necessary to assist implantation of free-floating cells onto peritoneal surfaces? Cell adhesion molecules. Corroborating observations include the fact that normal ovarian surface epithelium rarely expresses E-cadherin [19] but ovarian carcinomas express high levels of E-cadherin and other cell adhesion molecules [46]. Further, the 39-gene signature that is rich with key cell adhesion transscripts such as: CLDN1, FN1, MUC1, THBS1 and TNC, along with cytokines that promote or regulate adhesion, C1R6L1 and IL-8.

In summary, we have identified an LPA-driven, 39-gene signature that is sufficient on unsupervised clustering to predict worsened outcome in ovarian cancer. While some of the effect on outcome could be related to the signature enriched in serous epithelial tumors that are associated with a worsened outcome, this appears insufficient to explain the overall effect on tumor behavior. Thus, an LPA signature likely reflective of LPA function in ovarian cancer patients is highly enriched in a population of ovarian cancers. This could prove to be important in determining prognosis, in response to current therapy or in selecting patients for therapy targeting LPA. Claudin-1 is a leading candidate biomarker for such selection as LPA-targeted therapies move forward to clinical trials. This is particularly important as a series of inhibitors targeting LPA signaling, LPA production and LPA receptors are indeed in preclinical development [36]. In addition, the demonstration herein that LPA signaling alters outcome in ovarian cancer increases the impetus for clinical trials of drugs targeting this pathway.

Supporting Information

Figure S1 Comparison and validation of the LPA-induced gene expression transriptional profile in OVCAR-3 cells. Pairwise scatter plots demonstrate the microarray gene expression values of the triplicate samples under one experimental condition of either (A) control or (B) LPA-stimulated (18:1, 20 μM for 24 h) or (C) EGF-stimulated (20 μM for 24 h). In the first row of three plots the line represents sample 1 with itself (hyb.1), sample 1 with sample 2 (hyb.2) and sample 1 with sample 3 (hyb.3). The comparisons continue with the other rows so that the three plots on the upper right half are mirrors of the three in the lower half. Because the corresponding dots fall close within a 45° reference line, the replicated microarray chips are highly correlated, suggesting the reproducibility of each condition is high. (D) Quantitative RT-PCR of OVCAR-3 cells stimulated without or with LPA (20 μM) for the times indicated. The mRNA was extracted from OVCAR-3 cells and processed to corroborate transcript changes seen on the microarray. The data shown is the average of results from transcription factors and a co-repressor in OVCAR-3 and SKOV-3 cells relative to Beta-2 microglobulin. The Expression Analysis Systematic Explorer (EASE) software program was used to categorize microarray results into E celluar localization or (F) molecular function. The majority of genes are localized to regions affecting extracelluar signaling including the plasma membrane (30%), extracellular matrix (12%) or secretion into the extracellular space (20%). A variety of molecular functions are represented in the signature with cell-cell communication (21%) and signal transduction (14%) the most prominent categories.

Figure S2 Various ovarian cancer datasets demonstrate that the 39-gene signature characterizes serous EOC. (A) The patient dataset GSE66022 (N = 74) [25] was examined with the genes available contained in the 39-gene signature and hierarchical clustering separated a group (N = 19) that was strongly positive for the LPA-signature (far right cluster) and corresponded most closely with invasive serous EOC. (B) The patient dataset GSE10971 (N = 37) was divided into two groups based upon similarity to the LPA signature as determined by increased expression and hierarchical clustering (data not shown). All patients in the LPA-positive cluster (100%) had high-grade serous carcinoma while the majority of patients in the dissimilar cluster (N = 24 out of 25) had non-malignant fallopian tube epithelium carcinoma.

Figure S3 CLDN1 and cell adhesion-related proteins drive the clustering of the LPA transcriptomic signature. (A) The patient dataset, GSE66008, N = 103, was downloaded from the NCBI Entrez GEO DataSets website and analyzed using a previously-identified set of drivers, CLDN1, C1R6L1, FN1, IL-8, MUC1, THBS1, and TNC. These genes were capable of classifying the LPA-positive serous cluster of patient samples without the other genes comprising the 39-gene signature. Specimens (N = 79) isolated from patients treated at the Norwegian Radium Hospital...
re-examined by hierarchical clustering using only those available genes with a role in cell adhesion. Kaplan-Meier analysis of the different clusters indicates that the LPA-signature positive cluster has shorter median values for both disease-specific (B) and progression-free (C) survival compared to the LPA-negative cluster (D). Out of the seven clones, clone A, claudin-1 (CLDN1) was sufficient to differentiate serous from other EOC types. Serous EOC highly expresses CLDN1 whereas mucinous tumors, clear cell tumors and normal specimens were low and the majority of endometrioid samples are at the median level or below (N = 32, 89%).

References

1. Eder AM, Sasagawa T, Mao M, Aske J, Mills GB (2000) Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phosphodiase D and phospholipase D2. Clin Cancer Res 6: 2482–2491.
2. Umezu-Goto M, Tanji J, Lahad J, Liu S, Yu S, et al. (2004) Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem 92: 1115–1140.
3. Westermann AM, Hauk e, Postma FR, Beijnen JH, Dalesio O, et al. (1998) Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 9: 437–442.
4. Xiao YY, Schwartz B, Washington M, Kennedy A, Webster K, et al. (2001) Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 290: 302–313.
5. Shen Z, Belinson J, Morton RE, Xu Y, Xu Y (1996) Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol 71: 364–368.
6. Murphy MM, Nguyen GH, Radhakrishna H, Mills GB (2008) Sharpening the edges of understanding: the structure/function of the LPA1 receptor: expression, expression in cancer and mechanisms of regulation. Biochim Biophys Acta 1714: 547–557.
7. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, et al. (2002) Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochem Biophys Acta 1552: 257–264.
8. Mills GB, Moolenaar WH (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582–591.
9. Murphy MM, Nguyen GH, Radhakrishna H, Mills GB (2008) Sharpening the edges of understanding: the structure/function of the LPA1 receptor: expression, expression in cancer and mechanisms of regulation. Biochim Biophys Acta.
10. Tanji JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, et al. (2003) The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res 63: 1073–1082.
11. Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, et al. (2006) Carboxylesterase domain is essential for the regulation of phospholipase D activity in ovarian cancer cells. Cancer Res 66: 2643–2650.
12. Jermal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43–66.
13. Seidman JD, Kurman RJ (2003) Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 17: 909–923, viii.
14. Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, et al. (2008) Lysophosphatidic acid is a major regulator of growth-regulated onco-protein alpha in ovarian cancer. Cancer Res 68: 2740–2748.
15. Sakamoto S, Yokoyama M, Zhang X, Prakash K, Nagao K, et al. (2004) Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and in regulation by lysophosphatidic acid. Endocrinology 145: 2929–2940.
16. Reiner CO, Lanz T, Hofmann A, Hofer G, Rupprecht HD, et al. (1998) Lysophosphatidic acid-mediated signal-transduction pathways involved in the induction of the early-response genes prostaglandin G/H synthase-2 and Egr-1: a critical role for the mitogen-activated protein kinase p38α and for Rho proteins. Biochem J 330 (Pt 3): 1107–1114.
17. Schwartz BM, Hong G, Morrison BH, Wu W, Baudhuin LM, et al. (2001) Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Cancer Res 61: 291–300.
18. Checovich WJ, Mosher DF (1993) Lysophosphatidic acid enhances fibroblast binding to adherent cells. Arterioscler Thromb 13: 1662–1667.
19. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, et al. (1999) Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 5: 3704–3710.
20. Murphy M, Mills GB (2007) Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Med Biol 9: 1–18.
21. Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, et al. (2007) Gene expression profile of ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5: 355–366.
22. Weinberg RA, ed (2007) The Biology of Cancer. New York, NY: Garland Edition. 812 p.
23. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863–14868.
24. Oueldet Y, Prowencher DM, Maugard CM, Le Page C, Ren F, et al. (2005) Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 24: 4672–4677.
25. Hendrix ND, Wu R, Kucik R, Schwartz DR, Fearon ER, et al. (2006) Fibroblast growth factor-9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66: 1354–1362.
26. Parthey K, Levan K, Osterberg L, Horvath G (2006) Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer 42: 2892–2898.
27. Lajk V, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.
28. Wong X, Seed B (2003) A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 31: e154.
29. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, et al. (2001) Missing value estimation methods for DNA microarrays. Bioinformatics 17: 520–525.
30. Lee Z, Sway BJ, Liang Y, Yu S, Liu S, et al. (2006) Lysophosphatidic acid is a major regulator of growth-regulated onco-protein alpha in ovarian cancer. Cancer Res 66: 2740–2748.
31. acknowledgments

We would like to thank the following for their help with dataset analyses, Kwai Wa Cheng and Eun Sung Park.

Author Contributions

Conceived and designed the experiments: MMM YL GM. Performed the experiments: MMM SY HL HH JL MES AH GBK. Analyzed the data: MMM WL GM. Contributed reagents/materials/analysis tools: MMM MES AH GBK ALBD. Wrote the paper: MMM BTH GM.